Deals News - Pharmaceutical Executive


Deals News
Mergers, acquisitions, strategic partnerships, and product licensing. Plus, strategies and tactics for better deal-making

Sepracor Faces Shareholder Lawsuit in Wake of $2.6B Deal

September 9, 2009

Some shareholders think they were shafted in the multi-billion dollar deal between Sepracor and Dainippon Sumitomo Pharma. They're so miffed, in fact, that they've filed a lawsuit stating that the amount offered undervalues the company and its shares.

GSK Grabs Derma Firm for $2.9 Billion

April 22, 2009

Stiefel Labs is under new management. The dermatology company was purchased by GSK in an effort to bolster its existing skincare line.

Pfizer and Glaxo Join Forces in HIV Venture

April 22, 2009

The two pharma giants announced plans to form a new specialty company focused on HIV drug development. The new, independent firm will have a total of 11 drugs on the market, with another six on the horizon, securing its place as a powerhouse in the HIV market.

Gilead Buys CV Therapeutics (Update 1)

March 12, 2009

The morning's other big M&A news comes out of the Bay Area biotech industry, where Gilead Sciences announced that will purchase CV Therapeutics for $1.4 billion.

Roche and Genentech Seal the Deal for $46.8 Billion

March 5, 2009

After months and months of back and forth over the true value of Genentech, Roche finally got the good news it's been looking for: Genentech's board of directors, this morning, approved Roche's latest offer of $46.8 billion ($95 per share) to acquire all shares of the biotech giant.

Merck Takes Unusual Merger Tactic in Schering Deal

March 4, 2009

The Merck acquisition of Schering-Plough may have surprised few, the approach has raised some eyebrows. Rather than buy the company outright, Merck going through a convoluted reverse merger deal to keep Schering's licensing deals secure. Was it the right move?

Genentech and Roche May Be Close to Deal

March 3, 2009

All signs point to Genentech acquisition.

Astellas to Nominate Two Directors to CV Therapeutics Board

March 3, 2009

Astellas's hostile bid takes a new turn as the Japanese company tries to oust remaining CVT board members and replace them with their own.

Specialty Firms Shoot Down Big Money Bids

February 25, 2009

CV Therapeutics and Genetech rejected offers from big-name suitors. Are they playing hard to get or are they just not that into them?


Click here